Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)

Loverix, Liselore; Vergote, Ignace; Busschaert, Pieter; Vanderstichele, Adriaan; Boeckx, Bram; Venken, Tom; Harter, Philipp; Brems, Hilde; Nieuwenhuysen, Els Van; Pignata, Sandro; Baert, Thaïs; González-Martín, Antonio; Han, Sileny; Marth, Christian; Neven, Patrick; Colombo, Nicoletta; Berteloot, Patrick; Mäenpää, Johanna; Olbrecht, Siel; Laga, Tina; Sablon, Erwin; Pujade-Lauraine, Éric; Lambrechts, Diether; Gorp, Toon Van

doi:10.1016/s0090-8258(22)01299-9

Cited by 21 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, another academic network developed the “Leuven” HRD test as a part of the ENGOT European HRD initiative [ 73 ]. On a total of 468 ovarian cancer samples taken from the PAOLA-1/ENGOT-ov25 trial, researchers found a significant correlation between the results of the Leuven HRD and the Myriad myChoice PLUS test.…”

Section: Hrd In a Laboratory Routinementioning

confidence: 99%

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches

Mangogna

Munari

Pepe

et al. 2023

JPM

View full text Add to dashboard Cite

The inability to efficiently repair DNA double-strand breaks using the homologous recombination repair pathway is defined as homologous recombination deficiency (HRD). This molecular phenotype represents a positive predictive biomarker for the clinical use of poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors and platinum-based chemotherapy in ovarian cancers. However, HRD is a complex genomic signature, and different methods of analysis have been developed to introduce HRD testing in the clinical setting. This review describes the technical aspects and challenges related to HRD testing in ovarian cancer and outlines the potential pitfalls and challenges that can be encountered in HRD diagnostics.

show abstract

Section: Hrd In a Laboratory Routinementioning

confidence: 99%

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches

Mangogna

Munari

Pepe

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…Finally, these assays are expensive and require central analysis, two factors which are driving the development of academic assays such as AmoyDx HRD Focus Panel 32 and Leuven HRD test. 33 Alongside these institutional efforts, there is an international academic effort underway to identify more reliable, cost-effective HRD assays using samples from the PAOLA-1 trial.…”

Section: Reviewmentioning

confidence: 99%

Genomic testing in high-grade serous ovarian cancer: current options and future development

Devlin

Miller

2023

Int J Gynecol Cancer

View full text Add to dashboard Cite

Understanding the genomic complexity of high-grade serous ovarian cancer is now essential in guiding patient management, particularly in the first-line setting. Our knowledge in this area has expanded rapidly in recent years, with biomarkers developing in parallel to agents designed to exploit cancer-associated genetic aberrations. In this review we will take stock of the current landscape of genetic testing and look towards the future with developments that aim to refine personalized treatment paradigms and track treatment resistance in real time.

show abstract

“…The Leuven HRD test showed a similar impact of olaparib on median PFS as Myriad myChoice test. 136 Other integrative models based on mutational signatures have been developed. HRDetect 137 and Classifier of Homologous Recombination Deficiency (CHORD) 138 are HRD tests based on whole-genome sequencing (WGS) analysis.…”

Section: Biomarkers Of Resistance To Parpimentioning

confidence: 99%

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer

et al. 2023

View full text Add to dashboard Cite

Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of ‘synthetic lethality’ is exploited by PARPi in tumors with defects in DNA repair pathways, particularly homologous recombination deficiency. The use of PARPis has been increasing since its approval as maintenance therapy, particularly in the first-line setting. Therefore, resistance to PARPi is an emerging issue in clinical practice. It brings an urgent need to elucidate and identify the mechanisms of PARPi resistance. Ongoing studies address this challenge and investigate potential therapeutic strategies to prevent, overcome, or re-sensitize tumor cells to PARPi. This review aims to summarize the mechanisms of resistance to PARPi, discuss emerging strategies to treat patients post-PARPi progression, and discuss potential biomarkers of resistance.

show abstract

Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)

Cited by 21 publications

References 0 publications

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches

Genomic testing in high-grade serous ovarian cancer: current options and future development

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer

Contact Info

Product

Resources

About